Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study Evaluating the Efficacy and Safety of the Combination of Durvalumab With Etoposide and Platinum as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas (LCNECs) of the Lung

NCT06393816 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT06393816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06393816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study Evaluating the Efficacy and Safety of the Combination of Durvalumab With Etoposide and Platinum as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas (LCNECs) of the Lung
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Recruiting
Start date
June 13, 2024
Completion date
September 30, 2029
Enrollment
80 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

large cell neuroendocrine carcinoma of the lung